Compare AVX & LGVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AVX | LGVN |
|---|---|---|
| Founded | 2017 | 2014 |
| Country | United States | United States |
| Employees | 7 | N/A |
| Industry | Metal Fabrications | Medicinal Chemicals and Botanical Products |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 30.8M | 7.8M |
| IPO Year | 2020 | 2021 |
| Metric | AVX | LGVN |
|---|---|---|
| Price | $4.19 | $1.55 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $61.25 |
| AVG Volume (30 Days) | ★ 329.4K | 70.7K |
| Earning Date | 11-13-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 92.55 | 50.76 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,340,811.00 | $709,000.00 |
| Revenue This Year | $18,042.77 | $46.15 |
| Revenue Next Year | $12.21 | $396.46 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 3348.10 | N/A |
| 52 Week Low | $0.35 | $0.48 |
| 52 Week High | $7.38 | $7.60 |
| Indicator | AVX | LGVN |
|---|---|---|
| Relative Strength Index (RSI) | 43.34 | 33.66 |
| Support Level | $3.02 | $0.61 |
| Resistance Level | $6.25 | $7.30 |
| Average True Range (ATR) | 0.69 | 0.22 |
| MACD | -0.20 | -0.02 |
| Stochastic Oscillator | 7.05 | 17.83 |
AVAX One Technology Ltd is a digital infrastructure company focused on digital asset and computing infrastructure. The Company builds modular data centers in regions with access to energy resources, using behind-the-meter generation and microgrid design to provide compute capacity for AI and high-performance computing (HPC) workloads. In addition, the company mines Bitcoin in Alberta and Ohio, operating at a hashrate of approximately 300 PH/s. The Company also maintains an Avalanche digital asset treasury, accumulating AVAX and generating onchain yield through native staking and ecosystem participation.
Longeveron Inc is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. Its investigational product candidate is laromestrocel. Laromestrocel is a proprietary, scalable, allogeneic cellular therapy that has multiple potential modes of action that include pro-vascular, pro-regenerative, and anti-inflammatory mechanisms that collectively appear to promote tissue repair and healing. It is in clinical development of a single investigational product candidate, laromestrocel, for four potential indications: HLHS, Alzheimer's disease (AD), Pediatric Dilated Cardiomyopathy (pediatric DCM), and Aging-related Frailty. It operates in a single operating segment focused on developing regenerative medicines to address unmet medical needs.